Global Zollinger-Ellison Syndrome Treatment Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Zollinger-Ellison Syndrome Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Zollinger Ellison Syndrome Treatment Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 1.30 Billion
Diagram Market Size (Forecast Year)
USD 1.85 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Zollinger-Ellison Syndrome Treatment Market, By Diagnosis (Blood Test, CT scan Ultrasound, X-Ray and Others), Treatment (Chemotherapy, Surgical Resection and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.

Zollinger-Ellison Syndrome Treatment Market

Zollinger-Ellison Syndrome Treatment Market Analysis and Size

Around 25% people suffering from Zollinger-Ellison syndrome can be caused due to MEN-1. Zollinger-Ellison syndrome can occur at age; though, people are generally diagnosed between 20 and 50 years. The evolving research and developments for creating efficient and cost effective treatments launch of new medications are likely to boost the market's major growth as no such effective treatments are available in the market.  

Data Bridge Market Research analyses a growth rate in the zollinger-ellison syndrome treatment market in the forecast period 2023-2030. The expected CAGR of zollinger-ellison syndrome treatment market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 1.3 billion in 2022, and it would grow up to USD 1.85 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Zollinger-Ellison Syndrome Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Diagnosis (Blood Test, CT scan Ultrasound, X-Ray and Others), Treatment (Chemotherapy, Surgical Resection and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

GSK Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Bristol Myers Squibb Company (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Johnson & Johnson Services, Inc. (India), Lupin (India), Alembic Pharmaceuticals Limited (India), Baxter (U.S.), Wockhardt (India), Apotex Inc (Canada), Aurobindo Pharma (India), and Theravance Biopharma (U.S.)

Market Opportunities

  • Increase in the number of research and development activities   
  • The emergence of new varied treatments

Market Definition

A Zollinger-ellison syndrome is a type of condition that is characterized as a development of tumours in gastrinomas. Zollinger-ellison syndrome secretes a hormone named gastrin that forms excessive stomach acid in the stomach and can cause duodenal ulcers and diarrhoea. So the treatment is essential and for the treatment of zollinger-ellison syndrome takes place by eradicating the excess acid production, and treating the malignant tumor. Symptoms include burning in the abdomen, fatigue, abdominal pain, weakness, vomiting, weight loss and bleeding from stomach.

Zollinger-Ellison Syndrome Treatment Market Dynamics

Drivers

  • Growing Prevalence Of Zollinger-Ellison Syndrome

Zollinger-Ellison syndrome is present in 0.5 to 3 out of every 1 million persons yearly. The disorder is characteristically diagnosed in patients between the ages of 20 and 50 years. Men experience Zollinger-Ellison syndrome at a greater rate than women. Around 80% of cases of Zollinger-Ellison syndrome are distinct to any other illnesses; though, 20 to 25% of incidences are in patients with multiple endocrine neoplasia type 1, which is a rare genetic abnormality.

Opportunities

  • Growing Number Of Research And Development Activities    

The market growth is boosted by an increase in the number of R&D activities. This will provide advantageous opportunities for the growth in the zollinger-ellison syndrome treatment. The government is funding R&D initiatives to encourage researchers and pharmaceutical companies to develop advanced medicines. For instance, in March 2021, ESOMEPRAZOLE MYLAN is used to treat Zollinger-Ellison syndrome. Furthermore, in October 2019, Somac is also developed and used to treat Zollinger-Ellison syndrome. Somac is used to treat this condition where the stomach produces very huge amounts of acid, much more in ulcers and reflux disease. This medicine belongs to a group of medicines called proton pump inhibitors (PPIs).

  • The Emergence Of New Varied Treatments

The current growing research organizations in the market are armed with and utilize the knowledge of professionals in several clinical disciplines, that lead to major advances in understanding zollinger-ellison syndrome treatment. Several treatment methods such as antacids, proton pump inhibitors, phosphate binders, H2 antagonists, and others are expected to treat the patients effectively.

Restraints/Challenges

  • Alteration in Drug Pricing and Product Recalls

Changes in drug pricing rules and product recalls are expected to hamper revenue growth. For instance, in 2022. 252 blister packs of the oral disintegrating Lansoprazole delayed-release tablets, that are used to treat Zollinger Ellison syndrome, gastroesophageal reflux disease, and peptic ulcer disease, are being recalled by Dr. Reddy's Laboratories.

  • High Cost of Treatment

The huge expenditure which is required for the surgeries and treatment processes impede the market growth. Several market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.

This zollinger-ellison syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the zollinger-ellison syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Zollinger-Ellison Syndrome Treatment Market  Scope

The zollinger-ellison syndrome treatment market is segmented on the basis of diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

  • Blood Test
  • CT scan Ultrasound
  • X-Ray
  • Others

Treatment

  • Chemotherapy
  • Surgical Resection
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Zollinger-Ellison Syndrome Treatment Regional Analysis/Insights

The zollinger-ellison syndrome treatment market is analyzed and market size insights and trends are provided by diagnosis, treatment, distribution channel and end-user as referenced above.

The major countries covered in the zollinger-ellison syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market in the forecast period due to the presence of key product manufacturers and increasing research and development activities.

Asia-Pacific is considered to grow over the coming years due to increased new research and developments on zollinger-ellison syndrome treatment market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Zollinger-Ellison Syndrome Treatment Share Analysis

The zollinger-ellison syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to zollinger-ellison syndrome treatment market

Key players operating in the zollinger-ellison syndrome treatment market include:

  • GSK Plc. (U.K.)
  • Bayer AG (Germany)
  • Novartis AG (Switzerland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Pfizer Inc. (U.S.)
  • Bayer AG (Germany)
  • Bristol Myers Squibb Company (U.S.)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Johnson & Johnson Services, Inc. (India)
  • Lupin (India
  • Alembic Pharmaceuticals Limited (India)
  • Baxter (U.S.)
  • Wockhardt (India)
  • Apotex Inc (Canada)
  • Aurobindo Pharma (India)
  • Theravance Biopharma (U.S.)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Zollinger-Ellison Syndrome Treatment Market will be worth USD 1.85 billion in the forecast period by 2030.
The Zollinger-Ellison Syndrome Treatment Market growth rate is 4.50% during the forecast period.
Growing Prevalence Of Zollinger-Ellison Syndrome is the growth driver of the Zollinger-Ellison Syndrome Treatment Market.
The diagnosis, treatment, distribution channel, and end-user are the factors on which the Zollinger-Ellison Syndrome Treatment Market research is based.
Major companies in the Zollinger-Ellison Syndrome Treatment Market are GSK Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Bristol Myers Squibb Company (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Johnson & Johnson Services, Inc. (India), Lupin (India), Alembic Pharmaceuticals Limited (India), Baxter (U.S.), Wockhardt (India), Apotex Inc (Canada), Aurobindo Pharma (India), and Theravance Biopharma (U.S.).